Enzaplatovir (BTA-C585) 是一种口服有效的融合 (fusion) 抑制剂，有潜力用于呼吸道合胞病毒 (RSV) 感染的研究。
货号:ajcx34736
CAS:1323077-89-9
分子式:C20H19N5O3
分子量：377.4
溶解度:DMSO : 200 mg/mL (529.94 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Enzaplatovir (BTA-C585) is an orally bioavailable fusion inhibitor for respiratory syncytial virus (RSV) infection[1].

Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor[1].

[1]. Eric A F SimÕes, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.